Navigation Links
St. Renatus, LLC, with Guidance from the U.S. Food and Drug Administration, Has Established Readiness to Proceed to Phase 3 Trials for a New Needle-Free Dental Anesthetic
Date:3/7/2011

FORT COLLINS, Colo., March 7, 2011 /PRNewswire/ -- St. Renatus, LLC, the northern Colorado start-up Company dedicated to bringing to market a needle-free dental anesthetic, announced today that the company had a favorable End of Phase 2 review with the U.S. Food and Drug Administration (FDA), and agreed that in the near future, the company will proceed with conducting Phase 3 efficacy studies to determine the exact parameters for their nasal mist dental anesthetic achieving dental anesthesia in the maxillary arch.

St. Renatus and the FDA discussed details for both Phase 3 Adult and Pediatric studies to be conducted in the near future. Final revised protocols will be forwarded to the FDA in the coming weeks.

The Phase 2 clinical trial results submitted to the FDA indicated that the nasal mist is comparable to that of a standard needle-injected dental anesthetic.

"We are very pleased with how the nasal mist has performed in trials thus far, and with the outcome of our meetings with the FDA. We believe it represents a significant step forward for both St. Renatus and the field of Dentistry," said Steve Merrick, Chief Executive Officer for St. Renatus, LLC.

Initial consumer research for the nasal mist product found that if patients are given the choice between a nasal mist anesthetic and a needle-injected anesthetic, 90 percent of all patients are very or somewhat likely to choose the new product, and 23 percent are very likely to switch to a dentist offering the nasal spray option.(1)

96% of dentists surveyed expect to offer the new nasal mist anesthetic to their patients.(1)

Phase 3 clinical studies required by the FDA are expected to be completed in the second half of 2011. A New Drug Application will likely be filed in the latter part of 2011.

ABOUT ST. RENATUSSt. Renatus, LLC was founded to commercialize and distribute a new needle-free dental anesthetic in the form of a nasal mist that is designed to achieve dental anesthesia in the maxillary arch. St. Renatus aims to create a better experience for dentists and qualifying patients by conducting clinical trials on an accurate and sophisticated method to anesthetize the upper teeth without the risk and pain of a needle. For more information, please visit www.st-renatus.com or call 970.282.0156.St. Renatus, LLC1000 Centre AvenueFort Collins, CO 80526Toll Free: 1.888.NUMB314 (1.888.686.2314)P: 970.282.0156F: 970.221.4365Info@St-Renatus.comInvestment information:Jill ShoemakerVice President of Investor Relations(970) 231-3243 jshoemaker@st-renatus.com P: 970.282.0156Investor_Relations@St-Renatus.comFor More Information Contact:Christine KozsuchBurgess CommunicationsPhone: 267.257.5866 Toll Free: 888 846 5759Email: ckozsuch@burgesscom.comReferences:

(1) Research conducted by Industrial Research Center, Glen Mills, PA. February, 2011.


'/>"/>

SOURCE St. Renatus, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
2. Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance
3. Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
4. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
5. NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
6. Masimo Reports Fourth Quarter and Full Year 2010 Financial Results; Provides 2011 Guidance
7. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
8. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
9. Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government
10. Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
11. InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):